

List of works cited

Periodical Materials in English

- Anonymous, *Docetaxel: Alcoholic intoxication due to alcohol excipient: case report*, Reactions Weekly 13, Issue 1375 (Oct. 9, 2011).
- Anonymous, *Latanoprost SPC ends in top EU markets*, Generics bulletin, Jan. 13, 2012.
- Anonymous, *News & highlights from week 40*, 12 Curr. Pat. Gaz. 1, (2009).
- Anonymous, *Patent expiries to hit glaucoma drug market growth until 2018*, The Pharma Letter, Sept. 18, 2011.
- Christophe Baudouin, Luisa Riancho, Jean-Michel Warnet, Françoise Brignole, *In vitro Studies of Antiglaucomatous Prostaglandin Analogues: Travoprost with and without Benzalkonium Chloride and Preserved Latanoprost*, 48 Invest. Ophthalmol. Vis. Sci. 4123, (2007).
- Josef Drexler, *Astra Zeneca and the EU Sector Inquiry: when do patent filings violate competition law?*, Max Planck Institute for Intellectual Property and Competition Law Research Paper No. 12-02, (2012).
- Ernst R. Berndt, Iain M. Cockburn, Karen A. Grepin, *The impact of Incremental Innovation in Biopharmaceutical*, 24 Pharmacoeconomics 69, (2006).
- Steven C. Carlson, Willy Chang, *"Obviously" a challenge: Patent survival statistics*, 5 Ind. Biotechnol. 172, (2009).
- Curtis R Chong, David J. Sullivan Jr., *New Uses for old Drugs*, 448 Nature 645, 645 (2007).
- Ami J. Claxton, Joyce Cramer, Courtney Pierce, *A systematic review of the associations between dose regimens and medication compliance*, 23 Clin. Ther. 1296, (2001).
- Patrick J. Crowley, Luigi G. Martini, *Formulation design: new drugs from old*, 1 Drug Discovery Today: Therapeutic Strategies 537, (2004).
- John Crown, Michael O'Leary, Wei-Song Ooi, *Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience*, 9 (suppl. 2) The Oncologist 24, (2004).
- Philippe Daull, Ronald Buggage, Grégory Lambert, Marie O. Faure, Janet Serle, Rong F. Wang, Jean S. Garrigue, *A Comparative Study of a Preservative-Free Latanoprost Cationic Emulsion (Catioprost®) and a BAK-Preserved Latanoprost Solution in Animal Models*, J. Ocul. Pharm. Ther., (online ahead of print: June 6, 2012).
- M. Diestelhorst, Brigitta Almegård, *Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma*, 236 Graefe's Archive for Clinical and Experimental Ophthalmology 577, (1998).
- Joseph A. DiMasi, Cherie Paquette, *The Economics of Follow-on Drug Research and Development*, 22 Pharmacoeconomics 1, (2004).

- Gaurav Dwivedi, Sharanabasava Hallihosur, Latha Rangan, *Evergreening: A deceptive device in patent rights*, 32 Technology in Society 324, (2010).
- G. Emilien, M. Ponchon, C. Caldas, O. Isacson and J.-M. Maloteaux, *Impact of genomics on drug discovery and clinical medicine*, 93 Q. J. Med 391, (2000).
- O. Esposito, M. Bonfill, E. Moyano, M. Onrubia, M.H. Mirjalili, R.M. Cusidó, J. Palazón, *Biotechnological Production of Taxol and Related Taxoids: Current State and Prospects*, 9 Anti-Cancer Agents in Medicinal Chemistry 109, (2009).
- Ronald D. Fitzmartin, *The challenge of global electronic submission standards in the biopharmaceutical industry*, 32 Drug Inf. J. 745 (1998).
- Edd Fleming, Philip Ma, *Drug life-cycle technologies*, 1 Nat. Rev. Drug Disc. 751, (2002).
- John Fraher, *Life-Cycle Management: The Link to Drug Delivery*, 2 Drug Deliv. Tech. 158, (2002).
- George Frisvold, Kelly Day-Rubenstein, *Bioprospecting and Biodiversity Conservation: What happens when discoveries are made?*, 50 Ariz. L. Rev. (2007).
- Ulrich M. Gassner, *Supplementary protection certificates for combination products: new combinatorics?*, 7 J. Intell. Prop. L. & Pract. 52, (2012).
- Kate S. Gaudry, *Evergreening: a common practice to protect new drugs*, 29 Nat. Biotechnol. 876, (2011).
- Michele Giannino, *Patents: Beware of competition law! Relying on patents to extend protection for medicines may be anticompetitive*, 7 J. Intell. Prop. L. & Pract. 391, (2012).
- C. Scott Hemphill, Bhaven N. Sampat, *Evergreening, patent challenges, and effective market life in pharmaceuticals*, 31 J. Health Econ. 327, (2012).
- Leighton Howard, *Use of patents in drug lifecycle management*, 4 J. generic medicines 230, (2007).
- W. Kruse, W. Eggert-Kruse, J. Rampmaier, B. Runnebaum, E. Weber, *Dosage frequency and drug-compliance behaviour – a comparative study on compliance with a medication to be taken twice or four times daily*, 41 Eur. J. Clin. Pharm. 589, (1991).
- Dahlia Ismail, Mourad Amrane, Jean S. Garrigue, Ronald Buggage, *A phase II, randomized study evaluating the safety and efficacy of Catioprost® compared to Travatan Z® in subjects with glaucoma and ocular surface disease*, 89 Acta Ophthalmol. 188, (2011).
- M.A. Johnstone, *Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost*, 124 Am. J. Ophthalmol. 544, (1997).
- N.R. Labiris, M.B. Dolovich, *Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications*, 56 Br. J. Clin. Pharm. 600, (2003).
- Kevin Mack, *Reforming Inequitable Conduct to Improve Patent Quality: Cleansing Unclean Hands*, 21 Berkeley Tech. L. J. 147, (2006).
- Terry Mahn, *Protecting New Investments in Old Drugs*, Issue 2 FDLI Update Magazine 38 (2009), available at <http://www.fr.com>.

Periodical Material in German

Simon Klopschinski, *Arzneimittelrechtliche Genehmigungsverfahren, staatliche Preisfestsetzung und Kostenerstattung für Arzneimittel im Lichte des Patentschutzes – Rechtsprechungsübersicht Belgien, Deutschland, Frankreich und Österreich*, GRURInt. 993, (2011).

Johanna Müller-Graff, Filipe Fischmann, *Der Fall AstraZeneca: “Tool boxes“ im Arzneimittelsektor – wer hat die besseren Werkzeuge und welche sind erlaubt? Zum Urteil des Gerichts der Europäischen Union vom 1. Juli 2010, Rs. T-321/05*, 792 GRUR Int 1, (2010).

Non Periodical Material

John E. Calfee, White Paper on Pharmaceutical Market Competition Issues, June 2, 2008, available at <http://62.102.106.100/content/default.asp?PageID=559&DocID=4894>.

R. Thomas, *Patent “Evergreening”: Issues in Innovation and Competition*, Congressional Research Service, (Nov. 13, 2009).

OECD Policy Roundtables, “Roundtable on Generic Pharmaceuticals 2009” DAF/COMP(2009) 39, Oct. 5, 2010 at 148.

William C. Stewart, *Combination Therapy: Is the Whole Greater?*, Rev. Ophthalmol., Jun. 15, 2005.

Table of books

V. N. Bhat, *The Challenges of the new EU Pharmaceutical legislation* Pharmaceuticals Policy and Law, (1st ed. 2005).

Kim B. Clark, Steven C. Wheelwright, *Managing New Product and Process Development: Text and Cases*, (1st ed. 1993).

Bengt Domeij, *Pharmaceutical Patents in Europe*, (1st ed. 2000).

Jan I. Drayer, James P. Burns, *From Discovery to Market: The Development of Pharmaceuticals*, in BURGER’S MEDICINAL CHEMISTRY AND DRUG DISCOVERY, (1995).

Philip W. Grubb, *Patents for Chemicals, Pharmaceuticals and Biotechnology* (5th ed. 2010).

Sajiv K. Nair, Kevin E. Henegar, *Modern Drug Synthesis*, (1st ed. 2010).

Kristof Roos, Julia Pike, Andrew Brown, Stefan Becker, *Patent-related Barriers to Market Entry for Generic Medicines in the European Union*, (2008).

Ulrich Storz, *Biopatent Law: Patent Strategies and Patent Management*, (1st ed. 2012).

Derk Visser, *The annotated European patent convention*, (17th ed., 2009).